Solvonis Therapeutics plc (LON:SVNS)
London
· Delayed Price · Currency is GBP · Price in GBX 0.224
-0.001 (-0.44%)
Mar 9, 2026, 4:35 PM GMT
Solvonis Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | May '21 May 31, 2021 | 2020 - 2018 |
| Revenue | - | - | 0.59 | 0.54 | 0.38 | 0.52 | Upgrade
|
| Revenue Growth (YoY) | - | - | 8.30% | 44.37% | -27.80% | 57.58% | Upgrade
|
| Cost of Revenue | - | - | 0.45 | 0.24 | 0.2 | 0.03 | Upgrade
|
| Gross Profit | - | - | 0.14 | 0.3 | 0.17 | 0.49 | Upgrade
|
| Selling, General & Admin | 2.58 | 1.51 | 2.36 | 2.91 | 1.71 | 1.03 | Upgrade
|
| Other Operating Expenses | - | - | - | -0.02 | -0 | -0.1 | Upgrade
|
| Operating Expenses | 2.58 | 1.51 | 2.54 | 3 | 1.79 | 0.93 | Upgrade
|
| Operating Income | -2.58 | -1.51 | -2.4 | -2.7 | -1.62 | -0.44 | Upgrade
|
| Interest Expense | -0 | -0.06 | -0 | -0 | -0.01 | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | - | -0.01 | Upgrade
|
| EBT Excluding Unusual Items | -2.59 | -1.57 | -2.4 | -2.71 | -1.64 | -0.45 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | 0.13 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -0.72 | - | - | - | Upgrade
|
| Pretax Income | -2.6 | -1.45 | -3.12 | -2.71 | -1.64 | -0.45 | Upgrade
|
| Earnings From Continuing Operations | -2.6 | -1.45 | -3.12 | -2.71 | -1.64 | -0.45 | Upgrade
|
| Earnings From Discontinued Operations | 0.01 | -0.14 | - | - | - | - | Upgrade
|
| Net Income | -2.59 | -1.59 | -3.12 | -2.71 | -1.64 | -0.45 | Upgrade
|
| Net Income to Common | -2.59 | -1.59 | -3.12 | -2.71 | -1.64 | -0.45 | Upgrade
|
| Shares Outstanding (Basic) | 2,600 | 1,157 | 104 | 104 | 70 | 69 | Upgrade
|
| Shares Outstanding (Diluted) | 2,600 | 1,157 | 104 | 104 | 70 | 69 | Upgrade
|
| Shares Change (YoY) | 2177.31% | 1011.63% | 0.45% | 47.98% | 1.45% | 1.47% | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | -0.03 | -0.03 | -0.02 | -0.01 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | -0.03 | -0.03 | -0.02 | -0.01 | Upgrade
|
| Free Cash Flow | -1.72 | -1.13 | -1.45 | -3.08 | -0.44 | -0.18 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.03 | -0.01 | -0.00 | Upgrade
|
| Gross Margin | - | - | 24.02% | 55.35% | 46.12% | 94.23% | Upgrade
|
| Operating Margin | - | - | -408.18% | -498.34% | -431.96% | -85.39% | Upgrade
|
| Profit Margin | - | - | -531.52% | -499.08% | -435.62% | -86.73% | Upgrade
|
| Free Cash Flow Margin | - | - | -247.70% | -567.90% | -116.44% | -34.81% | Upgrade
|
| EBITDA | - | -1.34 | -2.23 | -2.59 | -1.54 | -0.36 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -69.62% | Upgrade
|
| D&A For EBITDA | - | 0.17 | 0.17 | 0.11 | 0.08 | 0.08 | Upgrade
|
| EBIT | -2.58 | -1.51 | -2.4 | -2.7 | -1.62 | -0.44 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -85.39% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.